← INTEGRATED BIOPHARMA INC (INBP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
INTEGRATED BIOPHARMA INC (INBP)
Pharmaceutical Preparations · market cap $6M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| temozolomide | Phase 2 | Cancer |
| PEG-Interferon a-2b + Ribavirin | Phase 3 | Chronic Hepatitis C Infection in HIV-Infected Persons |
| peginterferon alfa-2b (SCH 54031) | Phase 3 | Hepatitis C, Chronic |
Price & technical context
3-month
+5.6%
6-month
-36.7%
12-month
-32.1%
52-wk range
$0.15–$0.38
vs 50-day MA
+12.4%
vs 200-day MA
-22.7%
Realized vol
66.7%
Max drawdown
-62.5%
Daily closes through 2026-09-23. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INBP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.